Last updated on June 2019

Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma


Brief description of study

This is a single-arm, open-label, multicenter, phase 4 clinical trial to evaluate the efficacy and safety of brentuximab vedotin as a single agent in patients with relapsed or refractory Systemic Anaplastic Large Cell Lymphoma (SALCL).

Clinical Study Identifier: NCT01909934

Find a site near you

Start Over

ZNA Stuivenberg

Antwerpen, Belgium
  Connect »

UZ Leuven

Leuven, Belgium
  Connect »

The Christie

Manchester, United Kingdom
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.